证券研究报告·行业跟踪周报·机械设备 机械设备行业跟踪周报 24 年年报总结&未来展望——重点关注内需 复苏（通用、检测）&看好装备出海（工程机 械、油服、叉车、光伏设备等） 增持（维持） [Table_Tag] [Table_Summary] 1.推荐组合：北方华创、三一重工、中微公司、恒立液压、中集集团、拓荆科技、海天 国际、柏楚电子、晶盛机电、杰瑞股份、浙江鼎力、杭叉集团、迈为股份、先导智能、 长川科技、华测检测、安徽合力、精测电子、纽威股份、芯源微、绿的谐波、海天精 工、杭可科技、伊之密、新莱应材、高测股份、纽威数控、华中数控。 2.投资要点： 【工程机械】2024 年报&2025 年一季报总结：内需复苏超预期，工程机械行业有望迎 来国内外共振 我们选取了 A 股 13 家主营业务为工程机械的上市公司进行分析，2024 年/25Q1 板块 营业总收入同比提升 3%/11%，2024 年以来行业需求持续回暖。2024 年/2025 年一季度 13 家 A 股工程机械上市公司合计实现总营收 2905/803 亿元，同比+3%/+11%，营收端 增速持续提升，主要系①24H2 起农村水利建设带动土方机械特别 ...

证券研究报告·行业研究·专业服务 检测服务行业2024年&2025年一季报总结 板块增速企稳，关注内需复苏与高壁垒高增长的新兴赛道 首席证券分析师：周尔双 执业证书编号：S0600515110002 zhouersh@dwzq.com.cn 证券分析师：韦译捷 执业证书编号：S0600524080006 weiyj@dwzq.com.cn 2025年5月9日 请务必阅读正文之后的免责声明部分 1 检测服务板块相关公司 • 本报告分析基于A股19家主营业务为检测服务的上市公司。选取公司及其业绩及市场表现如下。 表：检测服务相关标的梳理（2025/5/4） | 证券代码 | 证券简称 | 2025/5/4 | | | | 2024/12/31 | | | | | 主要下游 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 市值（亿元） | 营业总收入 | YOY | 归母净利润 | YOY | 毛利率 | 归母净利 | ROE | PE-LYR | | | | | | （亿元） | | （亿元） | ...

在人口向大城市聚集的普遍趋势下，粤西茂名的高州、信宜、化州等县级市逆势向上，实现常住人口连 续3年正增长。统计数据显示，2021年至2024年3年间，信宜、高州新增城镇常住人口9.28万人。鉴江水 悠悠流淌，乡愁使人驻足停留，也让人回归守护，粤西小城里的年轻面孔更多了，新生活更"潮"了。 家门口创业就业 4月清晨的高州市根子镇柏桥村，荔枝花已谢，青果挂满枝头，柏桥村农创园园长林常珍一边巡园，一 边用手机直播荔枝的喜人长势。她创立的采鲜园果蔬专业合作社，正计划在村里举办技能提升培训班， 组织"新农人"学习荔枝种植、烘干和网络销售等知识，帮助更多"新农人"在家门口创业就业。 合作社成立6年来，带动就业2000多人，村农产品加工年产值达1亿元。"荔枝季，我们几乎天天组织社 员在网上直播卖荔枝，带货效果非常好，高峰期一天的订单量超过4000单。"林常珍说。 农创园电商中心一角，林常珍的2个儿子——"95后"返乡新农人丁贯阳、丁贯洲用一张背景板、一张桌 子和几组灯光搭起直播间。"这是我们自家酿造的荔枝蜜，采用传统技艺，保留最原始的荔乡风 味……"短短2年多，大学读电商专业的丁贯洲和学设计专业的丁贯阳就从实战中尝到了甜头 ...

Summary of Key Points Core Viewpoint - The company, China Automotive Engineering Research Institute Co., Ltd. (China Automotive Research), is actively engaging with investors to enhance understanding of its operational strategies and future plans, particularly in the context of the evolving automotive industry towards electrification, intelligence, connectivity, and low-carbon initiatives [1][2]. Group 1: Investor Communication and Engagement - The company held an investor communication meeting on May 9, 2025, in Chongqing to discuss its operational status and strategic execution for 2024 and the first quarter of 2025 [1]. - Various securities firms and investment management companies participated in the meeting, indicating a broad interest from the investment community [1]. Group 2: Industry Trends and Company Positioning - The automotive industry is undergoing significant changes due to the "new four modernizations" (electrification, intelligence, connectivity, and low-carbon), prompting testing institutions to shift from traditional compliance testing to new technology research and testing [2]. - China Automotive Research has a long history and is one of the earliest institutions to obtain regulatory testing qualifications, accumulating extensive experience in testing services and product development [3]. Group 3: Service Capabilities and Market Strategy - The company is enhancing its service capabilities by focusing on three main technical lines: safety, green technology, and user experience, while increasing R&D investment [3]. - It has established a comprehensive service capability that includes development, testing, certification, evaluation, and after-sales services, effectively addressing pain points in product development for automotive enterprises [3]. Group 4: Environmental and Health Initiatives - The company has launched the China Automotive Health Index and services in the "dual carbon" field, focusing on carbon emission accounting and green low-carbon assessments [4]. - The company is actively involved in setting new emission standards and expanding its capabilities in environmental testing, despite a slight decline in the overall market for automotive emission testing due to the rise of electric vehicles [4]. Group 5: Infrastructure Development and Internationalization - The construction of the East China headquarters is nearing completion, with 90% of equipment procurement achieved, expected to be operational by the end of 2025 [5]. - The company is focusing on internationalization, aiming to provide comprehensive quality technical services to support Chinese automotive enterprises in their global operations [5][6]. Group 6: Hydrogen Energy Initiatives - The National Hydrogen Energy Power Quality Inspection and Testing Center commenced operations in January 2024, providing testing services across the hydrogen energy industry chain [6][7]. - The company is developing hydrogen-related detection equipment and core components, with plans to expand into various hydrogen energy applications, including hydrogen power generation and storage [7].

Core Viewpoint - The company reported a revenue of 3.207 billion yuan for 2024, representing a year-on-year growth of 11.01%, and a net profit attributable to shareholders of 352 million yuan, up 76.59% year-on-year [1] Financial Performance - For the entire year of 2024, the gross margin and net margin were 47.21% and 11.21%, respectively, showing an increase of 4.93 percentage points and 4.07 percentage points year-on-year [2] - In Q4 2024, the company achieved a revenue of 1.047 billion yuan, a year-on-year increase of 13.11% and a quarter-on-quarter increase of 28.32%, with a net profit of 163 million yuan, up 145.18% year-on-year and 49.75% quarter-on-quarter [2] - The gross margin and net margin for Q4 2024 were 52.73% and 16.7%, respectively, reflecting a year-on-year increase of 10.52 and 8.17 percentage points [2] - For Q1 2025, the company reported a revenue of 618 million yuan, a year-on-year increase of 5.16% but a quarter-on-quarter decrease of 40.98%, with a net profit of 5 million yuan, up 302.86% year-on-year but down 97.05% quarter-on-quarter [2] Business Segmentation - The company generated revenue from various segments in 2024: measurement (750 million yuan), reliability (780 million yuan), life sciences (500 million yuan), electromagnetic compatibility (360 million yuan), integrated circuits (260 million yuan), and EHS evaluation (180 million yuan), with year-on-year growth rates of +3.8%, +17.5%, +2.7%, +10.2%, +26.3%, and +2.6%, respectively [3] - The gross margins for these segments were 50.5%, 50.9%, 39.8%, 54.9%, 45.2%, and 38.0%, with year-on-year changes of +2.4, +7.4, +8.8, +4.0, +4.3, and -6.49 percentage points [3] - The company focuses on emerging industries, with over 80% of its business coming from sectors such as special industries, automotive, new energy, integrated circuits, commercial aerospace, communication, low-altitude economy, and artificial intelligence [3] Shareholder Returns - The company conducted active market value management, distributing a total dividend of 224 million yuan for the year, with a mid-year dividend of 140 million yuan and a total of 614 million yuan in dividends and share buybacks, representing 174% of the annual net profit attributable to shareholders [4] - The projected net profits for 2025 to 2027 are 420 million yuan, 510 million yuan, and 600 million yuan, reflecting year-on-year growth rates of +20%, +20%, and +18%, respectively [4]

证券代码：300887 证券简称：谱尼测试 A：主要措施包括： 1、削减盈利能力较弱的建材、无损、能力验证、日消等业务板块，内 部整合食品、环境、医学实验室产能；基于公司内部资源整合，在资产负 债表日,对存在减值迹象的长期资产进行减值测试并确认减值损失。 2、加强应收账款管理、调整优化客户结构以及加强信用管理，对应收 账款等进行减值测试并确认减值损失。 谱尼测试集团股份有限公司投资者关系活动记录表 编号：2025-001 | | □特定对象调研 分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 ☑业绩说明会 | | 类别 | □新闻发布会  路演活动 | | | 现场参观 | | |  其他（电话会议） | | 活动参与人员 | 详见附件 | | 时间 | 2025 年 4 月 22 日-5 月 8 日 | | 地点 | 电话会议、网络业绩说明会 | | 上市公司接待 | 董事长 宋薇女士 | | 人员姓名 | 董事、董事会秘书 李小冬先生 | | | 副总、财务负责人 吕琦先生 | | | 一、介绍公司 2024 年度和 25 年一季度业绩情况 | | | 公司 202 ...

1 / 7 | 证券代码：300942 | 证券简称：易瑞生物 | 编号：2025-006 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 投资者关系活动记录表 | | 特定对象调研（线下） 分析师会议 | | | | | | --- | --- | --- | --- | --- | --- | | 投资者关系活 | 媒体采访 业绩说明会  | | | | | | 动类别 | 新闻发布会 路演活动 | | | | | | | 现场参观 其他 | | | | | | 参与单位名称 | 线上参与公司 2024 年度网上业绩说明会的投资者 | | | | | | 及人员姓名 | | | | | | | 时间 | 2025 5 15:00-17:00 | 年 | 月 | 7 | 日 | | 地点 | 全景网"投资者关系互动平台"（http://ir.p5w.net） | | | | | | | 董事长、总经理肖昭理先生 | | | | | | | 董事、副总经理、董事会秘书李文天女士 | | | | | | 上市 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for Q1 2025, attributed to external policy impacts and operational challenges, while also highlighting ongoing efforts to optimize operations and improve cash flow management [1][2][3] Financial Performance - In Q1 2025, the company achieved revenue of 2.365 billion yuan, a year-on-year decrease of 20.45% [1] - The net profit attributable to shareholders was -21 million yuan, a year-on-year decline of 190.66% [1] - The gross profit margin was 26.39%, an increase of 0.87 percentage points year-on-year, while the net profit margin was 0.18%, a decrease of 2.39 percentage points year-on-year [1] Business Segment Analysis - Diagnostic services revenue was 798 million yuan, down 30.55% year-on-year, primarily due to external policy factors [2] - Revenue from channel agency products was 1.576 billion yuan, a decrease of 15.13% year-on-year, impacted by centralized procurement [2] - Self-owned product revenue was 83 million yuan, an increase of 9.21% year-on-year, driven by the growth of specialty products [2] Cash Flow and Receivables Management - As of the end of Q1 2025, accounts receivable and notes totaled 7.477 billion yuan, a decrease of 999.8 million yuan year-on-year [2] - The net operating cash flow was -169 million yuan, an increase of 98 million yuan year-on-year, indicating improved cash flow management [2] Strategic Initiatives - The company is advancing its "digital + automation + AI" business model, forming strategic partnerships with major players like BGI and Ant Group to enhance capabilities in precision medicine and AI applications [3] - The focus on AI and digital transformation positions the company at the forefront of industry innovation [3] Revenue and Profit Forecast - Revenue projections for 2025-2027 are 12.381 billion, 13.117 billion, and 13.935 billion yuan, with expected year-on-year growth rates of 2%, 6%, and 6% respectively [3] - Forecasted net profit attributable to shareholders for the same period is 429 million, 738 million, and 930 million yuan, with growth rates of 220%, 72%, and 26% respectively [3]

导读： 近日，同济大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出16项仪器设备采购意向，预算总额达1.27亿元。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 中国医学科学院北京协和医院中央专项彩票公益金支持罕见病诊疗水平能力提升项目（第六期）公开招标公告 公告信息： 采购项目名称 中央专项彩票公益金支持罕见病诊疗水平能力提升项目（第六期） 行政区域 北京市 公告时间 2 0 2 5年0 4月3 0日 1 7 : 2 9 获取招标文件时间 2 0 2 5年0 4月3 0日至2 0 2 5年0 5月1 2日 每日上午: 8 : 0 0 至 1 4 : 0 0 下午: 1 2 : 0 0 至 2 1 : 0 0（北京时间，法定节假日除外） 招标文件售价 ￥4 0 0 获取招标文件的地点 本项目招标文件采用网上下载电子版本方式和纸质招标文件同时发放方式 开标时间 2 0 2 5年0 5月2 3日 0 9 : 0 0 开标地点 北京市丰台区西三环南路1 4号院首科大厦A座4层4 0 5号 预算金额 ￥4 8 0 ...

证 券 研 究 报 告 信测标准（300938）2024 年报及 2025 年一季报点评 强推（维持） 夯实精细化管理，打造通用机器人+AI 大模 型+检测新模式 事项： 公司发布 2024 年报以及 2025 年一季报：2024 年公司实现收入 7.25 亿元，同 比+6.71%，归母净利润 1.76 亿元，同比+7.67%，扣非归母净利润 1.65 亿元， 同比+10.77%；2025Q1 公司实现收入 1.66 亿元，同比-8.04%；归母净利润 3714.70 万元，同比-9.48%；扣非归母净利润 3428.99 万元，同比-9.45%。 评论： 公司研究 仪器仪表Ⅲ 2025 年 05 月 04 日 目标价：39.74 元 当前价：30.56 元 华创证券研究所 证券分析师：范益民 电话：021-20572562 邮箱：fanyimin@hcyjs.com 执业编号：S0360523020001 证券分析师：丁祎 邮箱：dingyi@hcyjs.com 执业编号：S0360523030001 公司基本数据 | 总股本(万股) | 16,450.77 | | --- | --- | | 已上市流通股 ...